QuidelOrtho (QDEL) Earnings Call Presentation

Acquisition of LEX Diagnostics - QuidelOrtho intends to acquire LEX Diagnostics for approximately $100 million at closing, pending FDA clearance expected in late 2025 or early 2026 [5] - An additional earnout component of up to $40 million may be payable for up to 6 years following the acquisition's closing [5] - The acquisition aims to strengthen QuidelOrtho's participation in the approximately $9 billion molecular diagnostics market [10] - LEX Diagnostics' system can report positive results in approximately 6 minutes with a single multiplex test for the detection and differentiation of Flu A, Flu B and COVID-19, while negative results can be reported in approximately 10 minutes [9] Discontinuation of Savanna Platform - QuidelOrtho plans to discontinue its Savanna platform development due to factors including recent clinical trial results [5] - No contribution from U S Savanna respiratory products is expected in 2025 [19] Financial Guidance - QuidelOrtho reaffirms its full-year 2025 financial guidance, with total revenues expected to be between $260 billion and $281 billion [17] - Adjusted EBITDA is projected to be between $575 million and $615 million, with an adjusted EBITDA margin of 22% [17] - Adjusted diluted EPS is expected to be in the range of $207 to $257 [17]